124832-26-4|伐昔洛韦|Valacyclovir|MFCD00866955-范德生物科技公司

伐昔洛韦

NMR下载 COA and HPLC MSDS下载
names：
Valacyclovir
CAS号：
124832-26-4
MDL Number： MFCD00866955
MF(分子式)： C13H20N6O4 MW(分子量)： 324.34
EINECS:1312995-182-4 Reaxys Number:
Pubchem ID:135398742 Brand:BIOFOUNT

伐昔洛韦(124832-26-4,Valacyclovir)是一种抗病毒药物，用于治疗单纯疱疹，带状疱疹和B型疱疹。IC50值：2.9微克/毫升（对于HSV-1 W）[4]。；目标：HSV感染；体外：VACV的摄取是浓度依赖性的并且可饱和，其Michaelis-Menten常数和最大速度分别为1.64 +/- 0.06 mM和23.34 +/- 0.36 nmol / mg蛋白/ 5 min。在hPEPT1 / CHO细胞，大鼠和兔子组织以及Caco-2细胞中获得了非常相似的Km值，这表明hPEPT1在体外VACV的肠道转运特性中占主导地位.

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000721-50mg	50mg		¥ 706.00	¥ 706.00		Backorder	- +	¥ 0.00
YZM000721-10mg	10mg	>97%	¥ 438.75	¥ 438.75		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	伐昔洛韦(124832-26-4);青霉素G盐-D7;万乃洛韦;L-缬氨酸2-（（2-氨基-1,6-二氢-6-氧代-9H-嘌呤-9-基）甲氧基）乙基;256U87;阿昔洛韦，L戊酯;阿昔洛韦，L-戊酸酯;BW256U87;D-伐昔洛韦;缬氨昔洛韦;L-戊酸酯阿昔洛韦;盐酸伐昔洛韦;盐酸伐昔洛韦（DL）-异构体;伐昔洛韦（D）-异构体;伐昔洛韦（DL）-异构体;伐昔洛韦（L）-异构体;伐昔洛韦，D-;伐昔洛韦，盐酸x，（D）-异构体;伐昔洛韦，x-盐酸盐，（DL）-异构体;瓦尔特雷克斯;
英文别名	Valacyclovir(124832-26-4);2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl L-valinate;256U87;Acyclovir, L valyl Ester;acyclovir, L-valyl ester;BW256U87;D- Valacyclovir;L Valylacyclovir;L-valyl Ester Acyclovir;L-valylacyclovir;valaciclovir;valacyclovir;valacyclovir hydrochloride;valacyclovir hydrochloride, (DL)-isomer;valacyclovir, (D)-isomer;valacyclovir, (DL)-isomer;valacyclovir, (L)-isomer;Valacyclovir, D-;valacyclovir, x-hydrochloride, (D)-isomer;valacyclovir, x-hydrochloride, (DL)-isomer;Valtrex;
CAS号	124832-26-4
SMILES	N[C@@H](C(C)C)C(OCCOCN1C=NC2=C1N=C(N)NC2=O)=O
Inchi	InChI = 1S / C13H20N6O4 / c1-7（2）8（14）12（21）23-4-3-22-6-19-5-16-9-10（19）17-13（15）18- 11（9）20 / h5,7-8H，3-4,6,14H2,1-2H3，（H3,15,17,18,20）/ t8- / m0 / s1
InchiKey	HDOVUKNUBWVHOX-QMMMGPOBSA-N
分子式 Formula	C13H20N6O4
分子量 Molecular Weight	324.34
闪点 FP	309.7°C
熔点 Melting point	204-208°C
沸点 Boiling point	588.4°C
Polarizability极化度
密度 Density	1.55±0.1 g/cm3(Predicted)
蒸汽压 Vapor Pressure
溶解度Solubility
性状	白色至灰白色结晶粉末
储藏条件 Storage conditions	请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.

伐昔洛韦(124832-26-4,Valacyclovir)毒理性质：
Oral therapy with valacyclovir is associated with a low rate of mild-to-moderate serum aminotransferase elevations, but these abnormalities are usually asymptomatic and self-limited even with continuation of therapy. Complicating the attribution of liver test abnormalities to valacyclovir therapy is the fact that enzyme elevations are not uncommon during the course of varicella-zoster infection (shingles) and can progress to clinically apparent hepatitis and even acute liver failure. Clinically apparent liver disease due to valacyclovir itself is rare, but isolated reports have been published. The time to onset was short (1 to 2 weeks) and the course mild, with few symptoms and rapid resolution (Case 1). The pattern of liver injury described was mixed hepatocellular-cholestatic. Immunoallergic features and autoantibodies were absent.

伐昔洛韦(124832-26-4,Valacyclovir)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:伐昔洛韦试剂,伐昔洛韦杂质,伐昔洛韦合成,伐昔洛韦密度,伐昔洛韦溶解度,伐昔洛韦旋光度,伐昔洛韦闪点,伐昔洛韦结构式,伐昔洛韦熔点,伐昔洛韦购买,

产品说明	伐昔洛韦(124832-26-4,Valacyclovir)是抗病毒化合物，对HSV-1 W的IC50为2.9μg/ ml。
Introduction	伐昔洛韦(124832-26-4,Valacyclovir)is an antiviral drug used in the management of herpes simplex, herpes zoster, and herpes B. IC50 Value: 2.9 microg/ml (for HSV W)[4].
Application1	Valaciclovir是一种抗病毒药物，用于治疗单纯疱疹，带状疱疹和B型疱疹。
Application2	伐昔洛韦是阿昔洛韦的左旋缬氨酸酯,是阿昔洛韦的前体药物。用于治疗水痘、带状疱疹及Ⅰ型、Ⅱ型单纯疱疹的感染,包括初发和复发的生殖器疱疹。
Application3

伐昔洛韦(124832-26-4,Valacyclovir)药理学：

1、伐昔洛韦是一种抗病毒药物，伐昔洛韦用于治疗单纯疱疹，带状疱疹和B型疱疹。

2、伐昔洛韦是抗病毒药物阿昔洛韦的L-戊酸酯的盐酸盐。口服给药时，伐昔洛韦迅速转化为无环鸟苷，其经过进一步转化为核苷酸类似物抑制病毒DNA复制阿昔洛韦三磷酸通过病毒胸苷激酶，细胞脒环化酶，以及许多其他细胞酶。三磷酸阿昔洛韦竞争性抑制病毒DNA聚合酶；整合并终止正在增长的病毒DNA链；并灭活病毒DNA聚合酶。阿昔洛韦的抗病毒活性更高与水痘带状疱疹病毒（VZV）相比，抗单纯疱疹病毒（HSV）的原因在于其可被HSV 胸苷激酶更有效地磷酸化。

3、伐昔洛韦是无环鸟苷的核苷类似物抗病毒剂和前药，用于治疗疱疹和水痘-带状疱疹病毒感染。伐昔洛韦与罕见的轻度，临床上明显的肝损伤有关。

4、伐昔洛韦是L-戊酸酯。它具有抗病毒药的作用。它来自鸟嘌呤。

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

伐昔洛韦(124832-26-4,Valacyclovir)危害标识：

象形图
信号	Warning
GHS危险说明	The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
GHS危险说明	H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
防范说明代码	P264, P270, P301+P312, P330, and P501
防范说明代码	(The corresponding statement to each P-code can be found at the GHS Classification page.)

Valacyclovir. New indication: for genital herpes, simpler administration. Can Fam Physician. 1999 Jul;45:1698-700, 1703-5.

Lycke J, Malmestr?m C, St hle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother. 2003 Aug;47(8):2438-41.

Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murineimmunosuppression model. Antimicrob Agents Chemother. 1995 May;39(5):1114-9.

Dhaliwal DK, Romanowski EG, Yates KA, Valacyclovir inhibits recovery of ocular HSV-1 after experimental reactivation by excimer laser keratectomy. Cornea. 1999 Nov;18(6):693-9.

Guo A, Hu P, Balimane PV, Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.J Pharmacol Exp Ther. 1999 Apr;289

伐昔洛韦(124832-26-4,Valacyclovir)参考文献：

1. Carbon nanotube based electrochemical sensor for the sensitive detection of valacyclovir
Badal Shah, Todd La?eur and Aicheng Chen*. Faraday Discuss., 2013, 164, 135–146

Substituted purines represent an important category of compounds that are actively used as therapeutic agents against viral infection. Valacyclovir is the drug of choice for the treatment of herpes zoster and cold sores. It is also e?ective for the treatment or suppression of genital herpes in immunocompetent individuals and for the suppression of recurrent genital herpes in HIV infected individuals. The chemical structure of valacyclovir is shown in Scheme 1. Valacyclovir is the L-valyl ester and prodrug of the antiviral drug acyclovir. Subsequent to absorption, valacyclovir is rapidly and almost completely hydrolyzed to acyclovir and L-valine, an essential amino acid, via first-pass metabolism. This hydrolysis is mediated primarily by the enzyme valacyclovir hydrolase and occurs predominantly in the liver. Because of the low bioavailability of acyclovir, its prodrug (valacyclovir) is preferred for therapeutic treatment, through which it plays an important role in the therapy of viral diseases. This drug provides significant therapeutic benefits in the treatment of viral diseases, and no serious side e?ects associated with its use have been reported in its monograph. Because of the wide use of valacyclovir in the treatment of di?erent viral diseases, its quantitative analysis has become very important and is under extensive study.

2. Spectro?uorimetric and TLC-densitometric methods for a stability indicating assay of valacyclovir hydrochloride in the presence of its degradation product
Sayed M. Derayea, Islam M. Mostafa and Mahmoud A. Omar*. RSC Adv.,2014, 4,42308–42315

Valacyclovir hydrochloride (VAC) is L-valine 2-[(2-amino-1,6-dihy-dro-6-oxo-9H-purin-9yl)methoxy]ethyl ester hydrochloride (Fig. 1). After its oral administration, VAC is rapidly converted into acyclovir which has demonstrated antiviral activity, against herpes simple xvirus type I (HSV-1),type 2 (HSV-II) and Varicella zoster virus. The oral bioavailability of acyclovir is higher after administration of VAC relative to acyclovir itself. The mechanism of action of acyclovir involves the highly selective inhibition of virus DNA replication, via enhanced uptake in virus-infected cells and phosphorylation by viral thymidine kinase. Few analytical methods have been reported for the determination of VAC. These methods include: spectrophotometric, chromatographic, capillary electrophoretic and electrochemical methods. To the present time there is no spectrofluorometric method reported for analysis of VAC. Accordingly we here present the first attempt for spectrofluorimetric method in addition to TLC-densitometry for the determination of VAC in pure form and pharmaceutical tablets.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开